Meningioma Market is Projected to Witness Steady Growth by 2036 Owing to Advancements in Diagnostic Technologies and Emerging Systemic Therapies | DelveInsight

The Meningioma market is projected to witness steady growth through 2036, supported by more diagnosed patients and advances in diagnostic neuroimaging. According to DelveInsight’s report “Meningioma Market Insights, Epidemiology, and Market Forecast - 2036,” the market growth is also linked to a rising incidence of recurrent and high-grade meningiomas and increasing research into targeted and investigational therapies. The report highlights the candidate NEO100 from NeOnc Technologies Holdings as part of a developing treatment pipeline. DelveInsight expects the indicative market value across the seven major markets (7MM) to rise from 10 in 2022 to 16 by 2036. The United States is forecast to lead by market size, while epidemiology cited includes a 97.5 per 100,000 U.S. prevalence rate and UK meningiomas representing about 27% of diagnosed brain tumors (1995–2017).